Ioannidis, John P. A. (2020) ‘The Infection Fatality Rate of COVID-19 Inferred from Seroprevalence Data’. MedRxiv. https://doi.org/10.1101/2020.05.13.20101253.

Thompson, D. (2021, February 17). COVID-19 Cases Are Dropping Fast. Why? The Atlantic. https://www.theatlantic.com/ideas/archive/2021/02/why-covid-19-cases-are-falling-so-fast/618041/

Imperial College London. ‘Report 34 - COVID-19 Infection Fatality Ratio Estimates from Seroprevalence’. Accessed 12 March 2021. http://www.imperial.ac.uk/medicine/departments/school-public-health/infectious-disease-epidemiology/mrc-global-infectious-disease-analysis/covid-19/report-34-ifr/.

Sabino, Ester C., Lewis F. Buss, Maria P. S. Carvalho, Carlos A. Prete, Myuki A. E. Crispim, Nelson A. Fraiji, Rafael H. M. Pereira, u. a. „Resurgence of COVID-19 in Manaus, Brazil, despite High Seroprevalence“. The Lancet 0, Nr. 0 (27. Januar 2021). https://doi.org/10.1016/S0140-6736(21)00183-5.

Aziz, N. A., Corman, V. M., Echterhoff, A. K. C., Richter, A., Schmandke, A., Schmidt, M. L., Schmidt, T. H., Vries, F. M. D., Drosten, C., & Breteler, M. M. B. (2020). Seroprevalence and correlates of SARS-CoV-2 neutralizing antibodies: Results from a population-based study in Bonn, Germany. MedRxiv, 2020.08.24.20181206. https://doi.org/10.1101/2020.08.24.20181206

Mandavilli, A. (2020, June 18). You May Have Antibodies After Coronavirus Infection. But Not for Long. The New York Times. https://www.nytimes.com/2020/06/18/health/coronavirus-antibodies.html

Benjamin Meyer on Twitter: “1. Since there was a huge discussion about T-cell mediated immunity following the Lancet comment on seroprevalence by @EckerleIsabella and me, I’d like to share my thoughts on this in the following thread:” / Twitter. (n.d.). Twitter. Retrieved July 8, 2020, from https://twitter.com/BenjaminMeyer85/status/1280257221587320835

Levin, A. T., Cochran, K. B., & Walsh, S. P. (2020). Assessing the Age Specificity of Infection Fatality Rates for COVID-19: Meta-Analysis & Public Policy Implications (Working Paper No. 27597; Working Paper Series). National Bureau of Economic Research. https://doi.org/10.3386/w27597

Arora, Rahul K., Abel Joseph, Jordan Van Wyk, Simona Rocco, Austin Atmaja, Ewan May, Tingting Yan, et al. ‘SeroTracker: A Global SARS-CoV-2 Seroprevalence Dashboard’. The Lancet Infectious Diseases 0, no. 0 (4 August 2020). https://doi.org/10.1016/S1473-3099(20)30631-9.

Havers, F. P., Reed, C., Lim, T., Montgomery, J. M., Klena, J. D., Hall, A. J., Fry, A. M., Cannon, D. L., Chiang, C.-F., Gibbons, A., Krapiunaya, I., Morales-Betoulle, M., Roguski, K., Rasheed, M. A. U., Freeman, B., Lester, S., Mills, L., Carroll, D. S., Owen, S. M., … Thornburg, N. J. (2020). Seroprevalence of Antibodies to SARS-CoV-2 in 10 Sites in the United States, March 23-May 12, 2020. JAMA Internal Medicine. https://doi.org/10.1001/jamainternmed.2020.4130

Seroprevalence and Black voices in healthcare—The Lancet Voice. (n.d.). Retrieved July 20, 2020, from https://www.buzzsprout.com/861868/4491443-seroprevalence-and-black-voices-in-healthcare

Larremore, Daniel B., Kate M. Bubar, and Yonatan H. Grad. Implications of test characteristics and population seroprevalence on ‘immune passport’ strategies (May 2020).https://dash.harvard.edu/handle/1/42664007